<div id="readability-page-1">By John Vandermosten, CFA NASDAQ: BLRX READ THE FULL BLRX RESEARCH REPORT BioLineRx Ltd. (NASDAQ: BLRX) reported 2025 financial and operational results in a March 23rd, 2026, press release. For the year, it produced license revenues of $1.2 million and a net operating loss of $10.3 million. The joint venture (JV) with Hemispherian, called Tetragon Biosciences, expects to begin screening patients by the end of this month for the glioblastoma...</div>

BLRX

紐交所高增長板生物技術指數 ETF - First Trust

<p>BioLineRx Ltd.（納斯達克代碼：BLRX）公佈了其 2025 財務業績，顯示許可收入為 120 萬美元，淨運營虧損為 1030 萬美元。該公司宣佈與 Hemispherian 的合資企業 Tetragon Biosciences 計劃在 2026 年 3 月底之前開始對膠質母細胞瘤患者進行篩查</p>

Bioline RX：2025 全年業績